BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

VIVUS, Inc. (VVUS) Says It's Victim of False Statements, Delays Shareholder Meet


7/15/2013 7:44:32 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

U.S. drugmaker Vivus Inc, locked in a proxy battle with First Manhattan Co, said paid advisors of the activist investor had made misleading statements and the company would be delaying its annual shareholder meeting by three days so that the matter could be dealt with. Vivus said the advisors to its top investor had made false and misleading to shareholders regarding the recommendation of proxy advisory firm Institutional Shareholder Services (ISS) but did provide details as to what the statements were. It has reported the matter to the U.S. Securities and Exchange Commission, asking that the regulator force FMC to correct them, it said in a news release. FMC, a New York-based investment advisory firm with a 9.9 percent stake in Vivus, has repeatedly criticized the company, saying it badly mishandled the launch of its obesity drug Qsymia and failed to land a large company partner with deep pockets and a big enough sales force to help the drug reach its blockbuster potential.

Help employers find you! Check out all the jobs and post your resume.


Read at Reuters
Read at Seeking Alpha
Read at Wall Street Journal

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES